

Division of Signal Transduction Therapy

Standard Operating Procedure

Preparation of active RSK2 [2 - 740]

<u>Enzyme description:-</u>	RSK2 [2 - 740]
<u>Clone number:-</u>	DU 1846
<u>Source:-</u>	Recombinant
<u>Expression system:-</u>	Baculovirus expression vector system
<u>Tag:-</u>	N-terminal His(6)
<u>Purification method:-</u>	Ni ²⁺ -NTA agarose
<u>Expression level:-</u>	5-10 mg/L
<u>Calculated molecular mass:-</u>	84, 678 daltons
<u>Purity:-</u>	>95 %

Activation protocol:-

RSK2 (2 µM) is activated by incubation with 5 U/ml GST-p42MAPKinase [DU 650 or DU 1844] and 1 U/ml GST-PDK1 [DU 954] in 50 mM Tris-HCl pH 7.5, 0.1mM EGTA, 0.1 % 2-mercaptoethanol, 10 mM magnesium acetate, 0.1 mM ATP for 30 min at 30 °C. Following activation, the active MAPKAP-K1b is repurified by Ni²⁺-NTA agarose chromatography.

Enzyme storage buffer:-

50 mM Tris-HCl pH 7.5, 270 mM sucrose, 150 mM NaCl, 0.1mM EGTA, 0.1 % 2-mercaptoethanol, 0.02 % Brij-35, 1 mM benzamidine, 0.2 mM PMSF.

Storage temperature:- -70 °C

Assay:- Standard filter binding assay

Assay buffer:-

50 mM Tris-HCl pH 7.5, 0.1 % 2- mercaptoethanol, 0.1 mM EGTA, 10 mM MgAc

Division of Signal Transduction Therapy

Substrate:-

Long S6 [KEAKEKRQEIQAKRRRLSSLRASTSKSGGSQK]

Final concentration: 30 μ M

Specific activity range:-

500 – 1000 U/mg

Division of Signal Transduction Therapy

Clone Data Sheet

RSK2 [2 - 740]

<u>Protein</u>	RSK2 [2 - 740]
<u>Clone number</u>	DU 1846
<u>Species</u>	Human
<u>Accession number</u>	NM_004586
<u>Tags</u>	N-terminal His(6)
<u>Baculovirus expressed protein</u>	MAHHHHHHGSPLAQLADPWQKMAVESPSDSAENGQQIMDEPMGEEEINP QTEEG G SIKEIAITHHVKEGHEKADPSQFELLKVLGQGSFGKVFLVKKIS GSDARQLYAMKVLKKATLKVRDRVRTKMERDILVEVNHPFIVKLHYAFQ TEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSL GIIYRDLKPENILLDEEGHIKLTDFGLSKESIDHEKKAYSFCGTVEYMA PEVNNRRGHTQSADWWSFGVLMFEMLTGTLPPFQGKDRKETMTMILKAKL GMPQFLSPEAQSLRLMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNK LYRREIHPPFKPATGRPEDTFYFDPEFTAKTPKDSPGIPPSANAHQLFR GFSFVAITSDDDESQAMQTVGVHSIVQQLHRNSIQFTDGYEVKEDIGVGS YSVCKRCIHKATNMEFAVKIIDKSKRDPTEEIEILLRYGQHPNIITLKD VYDDGKYVYVVTLMKGGELLDKILRQKFFSEREASAVLFTITKTVEYL HAQGVVHRDLKPSNILYVDESGNPESIRICDFGFAKQLRAENGLLMTPC YTANFVAPEVLKRQGYDAACDIWSLGVLLYTMLTGYTPFANGPDDTPEE ILARIGSGKFSLSGGYWNSVSDTAKDLVSKMLHVDPHQRLTAALVLRHP WIVHWDQLPQYQLNRQDAPHLVKGAMAATYSALNRNQSPVLEPVGRSTL AQRRGIKKITSTAL
<u>Native sequence</u>	Amino acids P2 – L740 (end) of human RSK2. Residue P11 of the fusion protein is equivalent to P2 of the native enzyme. The His(6) tag is located at residues 3 – 8. The following amino acid substitution is present: V – G, where V45 of the native sequence is G54 of the fusion protein.
<u>Protease cleavage</u>	None
<u>Cloning sites</u>	<i>Nde</i> 1 and <i>Xho</i> 1 sites of modified pFastBAC 1.

Division of Signal Transduction Therapy

Complete nucleotide sequence

ATGGCGCATCACCATCACCATCACGGATCCCCGCTGGCGCAGCTGGCGG
ACCCGTGGCAGAAGATGGCTGTGGAGAGCCCTTCCGACAGCGCGGAGAA
TGGACAGCAAATTATGGATGAACCTATGGGAGAGGAGGAGATTAACCCA
CAAACCTGAAGAAGGCAGTATCAAAGAAATTGCAATCACACATCATGTGA
AGGAAGGACATGAAAAGGCAGATCCTTCCCAGTTTGAACTTTTAAAGT
ATTAGGGCAGGGATCATTTGGAAAGGTTTTCTTAGTTAAAAAATCTCA
GGCTCTGATGCTAGACAGCTTTATGCCATGAAAGTATTAAGAAGGCCA
CGCTGAAAGTTCGAGACCGTGTTCCGACAAAAATGGAACGTGATATCTT
GGTAGAAGTCAATCACCTTTTATTGTCAAATTGCATTACGCTTTTCAA
ACGGAAGGGAAGTTGTATCTTATTTTGGATTTTCTCAGGGGCGGAGACT
TGTTTACACGCTTATCCAAAGAGGTGATGTTTACAGAGGAAGATGTCAA
ATTCTACTTGGCTGAACTTGCACTTGCTTTAGACCATCTTCATAGCCTG
GGAATAATCTATAGAGACTTAAAACCAGAAAACATACTTCTTGATGAAG
AAGGTCACATCAAGTTAACTGATTTTGGCTTAAGTAAGGAATCTATTGA
TCATGAGAAGAAGGCTTATTCTTTTTGTGGCACTGTGGAATACATGGCT
CCAGAAGTAGTTAACCGCAGAGGTCACACTCAGAGTGC GGACTGGTGGT
CCTTTGGTGTGTTGATGTTTGAATGCTCACTGGTACACTACCTTTCCA
AGGAAAAGATCGTAAAGAAACAATGACTATGATTCTTAAAGCCAACTC
GGGATGCCACAGTTTCTGAGTCCTGAAGCCCAGAGTCTTTTACGAATGC
TTTTCAAACGGAATCCTGCAAACAGATTAGGTGCTGGACCAGATGGAGT
TGAAGAAATTTAAAGACATTCATTTTTCTCAACAATAGACTGGAATAAA
CTATATAGAAGAGAGATTACCCACCTTTTAAGCCTGCAACTGGCAGAC
CTGAAGATACATTTTATTTTGATCCTGAGTTTACTGCAAAAACCTCCCAA
AGATTCACCGGGCATTCCACCTAGTGCTAACGCACATCAGCTTTTTTCGG
GGGTTTAGTTTTGTTGCTATTACCTCAGATGATGAAAGCCAAGCTATGC
AGACAGTTGGTGTGCATTCAATTGTTTACAGCAATTACACAGAAACAGTAT
TCAGTTTACTGATGGATATGAAGTAAAAGAGGATATTGGCGTTGGCTCA
TACTCCGTTTGTAAGAGATGTATACATAAAGCTACAAACATGGAGTTTG
CCGTGAAGATTATTGATAAAAGCAAGAGAGACCCAACAGAAGAGATTGA
AATTCTTCTTCGCTATGGACAGCATCCAAACATCATTACCCTAAAGGAT
GTGTATGATGATGGAAAATATGTGTATGTAGTAACAGAACTTATGAAAG
GAGGTGAATTGCTGGATAAGATTCTTAGACAGAAGTTTTTCTCAGAGCG
AGAGGCCAGCGCTGTCCTGTTTACTATAACCAAACTGTTGAGTATCTT
CATGCACAAGGGGTGGTTCACAGAGACTTGAAACCTAGCAACATTCTTT
ATGTGGATGAGTCTGGTAATCCAGAATCTATTCGAATTTGTGATTTTGG
CTTTGCAAAACAACTGAGAGCAGAAAATGGTCTTCTCATGACTCCTTGT
TATACTGCAAATTTTGTGACCAGAGGTTTTTAAACGGCAAGGTTATG
ATGCTGCCTGTGATATATGGAGTCTTGGCGTCCTCTTTATACAATGCT
TACTGGTTACACTCCATTTGCAAATGGCCCTGATGATACTCCAGAGGAA
ATACTGGCACGAATAGGTAGTGGAAAATTCTCACTCAGTGGTGGTACT
GGAATTCTGTTTCAGACACAGCAAAGGACCTGGTGTCAAAGATGCTTCA
TGTAGATCCTCATCAGAGACTGACGGCTGCTCTGGTGTCTCAGACATCCT

Division of Signal Transduction Therapy

TGGATTGTCCACTGGGACCAACTACCACAATACCAACTAAACAGACAGG
ATGCGCCGCATCTCGTAAAGGGTGCCATGGCAGCTACGTACTCTGCTTT
AAACCGCAATCAGTCCCCAGTCTTGGAACCAGTGGGCCGCTCCACTCTT
GCTCAGCGGAGAGGGATTAAAAAATCACCTCAACAGCCCTGtga